-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OzjLL4g9r1DsLR5WrLVL3ri7dMkJI/elAi5bWPvfaYBe4He7Ye+hNbrEI9Gc/1MC
 S+YIiCt1JVub6eR5NMMb8Q==

<SEC-DOCUMENT>0000950123-09-011247.txt : 20090604
<SEC-HEADER>0000950123-09-011247.hdr.sgml : 20090604
<ACCEPTANCE-DATETIME>20090604093511
ACCESSION NUMBER:		0000950123-09-011247
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090604
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090604
DATE AS OF CHANGE:		20090604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELECTRO OPTICAL SCIENCES INC /NY
		CENTRAL INDEX KEY:			0001051514
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133986004

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51481
		FILM NUMBER:		09873111

	BUSINESS ADDRESS:	
		STREET 1:		3 WEST MAIN STREET, SUITE 201
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
		BUSINESS PHONE:		914-591-3783

	MAIL ADDRESS:	
		STREET 1:		3 WEST MAIN STREET, SUITE 201
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y77630e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): June&nbsp;4, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Electro-Optical Sciences, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-51481</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3986004</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>3 West Main Street, Suite&nbsp;201,</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>10533</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Irvington, New York</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code <B>(914)&nbsp;591-3783</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Former name or former address, if changed since last report.)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))

</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;8.01 &#151; Other Events</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01 &#151; Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="y77630exv99w1.htm">EX-99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "Item&nbsp;8.01 &#151; Other Events" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 &#151; Other Events</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On June&nbsp;4, 2009, the Registrant issued a press release announcing the submission to the U.S. Food
and Drug Administration of its premarket approval application for MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. A copy of
the press release is attached as Exhibit&nbsp;99.1 to this report and is incorporated herein by
reference.
</DIV>

<!-- link1 "Item&nbsp;9.01 &#151; Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 &#151; Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits<I>.</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT NO.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of the Registrant, dated June&nbsp;4, 2009, titled
&#147;Electro-Optical Sciences Submits MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Pre-Market
Approval Application to FDA&#148;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Electro-Optical Sciences, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: June 4, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Richard I. Steinhart
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>
<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT INDEX
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT NO.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of the Registrant, dated June&nbsp;4, 2009, titled
&#147;Electro-Optical Sciences Submits MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Pre-Market
Approval Application to FDA&#148;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y77630exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="y77630y7763000.gif" alt="(EOS LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Electro-Optical Sciences Submits MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Pre-Market Approval<BR>
Application to FDA</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IRVINGTON, NY (June&nbsp;4, 2009) &#151; Electro-Optical Sciences, Inc. (&#147;EOS&#148;) (NASDAQ: MELA) today
announced the submission to the United States Food and Drug Administration (FDA)&nbsp;of its Premarket
Approval (PMA)&nbsp;application for MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, a non-invasive, point-of-care instrument to
assist in the early diagnosis of melanoma, the leading cause of death from skin cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Positive top line data from the MelaFind pivotal study, the largest prospective clinical study ever
conducted in melanoma detection, were announced in February and subsequently presented at several
major international dermatology meetings in March and May of this year. The company&#146;s final
analysis of the data demonstrated that for all subgroups analyzed, the sensitivity of MelaFind was
greater than 95% (lower confidence bound) and MelaFind specificity was statistically significantly
higher than that of study clinicians. As announced previously, the FDA has granted Expedited
Review for the MelaFind PMA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We believe the final results of the MelaFind<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>pivotal study met the study endpoints and
that the pivotal trial satisfied the specifications of the Protocol Agreement with the FDA under
which it was conducted,&#148; said Joseph V. Gulfo, MD, President &#038; CEO. &#147;We look forward to working
with the FDA in the review of the MelaFind application.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Melanoma</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Melanoma is the deadliest form of skin cancer, responsible for approximately 80% of skin cancer
fatalities. The melanoma rate has continued to increase with an estimated 120,000 new cases
projected in 2009. A recent National Cancer Institute report published in the July&nbsp;10, 2008 online
edition of the Journal of Investigative Dermatology indicates that annual incidence of melanoma
among young adult Caucasian women rose 50% between 1980 and 2004. Melanoma is the most common
cancer in women age 25 to 29 and the number one cancer killer of women age 30 to 35. Although no
cure is currently available for advanced-stage melanoma, if caught early, melanoma is virtually
100% curable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Electro-Optical Sciences</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Electro-Optical Sciences is a medical technology company focused on developing MelaFind, a
non-invasive and objective computer vision system intended to aid in the early detection of
melanoma. EOS designed MelaFind to assist in the evaluation of pigmented skin lesions, including
atypical moles, which have one or more clinical or historical characteristics of melanoma, before a
final decision to biopsy has been
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rendered. MelaFind acquires and displays multi-spectral (from
blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis
and statistical pattern recognition to help identify lesions to be considered for biopsy to rule
out melanoma.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more
information on EOS, visit <u>www.eosciences.com</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Safe Harbor
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release includes &#147;forward-looking statements&#148; within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not limited to our plans,
objectives, expectations and intentions and other statements that contain words such as &#147;expects,&#148;
&#147;contemplates,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;believes&#148; and variations of such words or
similar expressions that predict or indicate future events or trends, or that do not relate to
historical matters. These statements are based on our current beliefs or expectations and are
inherently subject to significant uncertainties and changes in circumstances, many of which are
beyond our control. There can be no assurance that our beliefs or expectations will be achieved.
Actual results may differ materially from our beliefs or expectations due to economic, business,
competitive, market and regulatory factors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For further information contact:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors<BR>
David Carey<BR>
Lazar Partners Ltd.<BR>
212-867-1768

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Media<BR>
Hollister Hovey<BR>
Lazar Partners Ltd.<BR>
646-871-8482

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y77630y7763000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y77630y7763000.gif
M1TE&.#EAM`!>`.8``%REQZ/)V^/J[IG$V?'T]5ZHR7>'H_CZ^8F6L8B[T^SQ
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MQURGR5ZEQ_W^^E^FRF^PS5:FR5>HROS]_H[`USU2?5>DQ=7F[J_/WKO9YUJJ
MREVJRF>FQ_[]_>[T]5>HQERHRUFCQ_W]_?W]_/S]_?S]_/S\_/W\^_W\_?O\
M_?O[^U^BQOS]^O[]_OW^^ZZ\SFBJR;?6X\;.V_[^_EZGR?___R'Y!```````
M+`````"T`%X```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O(-]?2(BO\*_?3+`'L;%?3K!
M(A[!OY?#PC+6P,O&UM?5P\O'?8[7R]#>X^"_Z#K&P=LRK!X2=FUM*BIM'BI2
M*AX>;W8O7N"Q\T:'!SHJWO1KT&`:,!%O_K'I8Z^B%!GM9+#Q4$_%$7KV1!R;
MV,B:&S8Z*AZAL^]?P!<-[.EH`S`@P3[]AKU;A3-E1'YM&#8X0("(@!MA2)`(
M<X,`G`;^&M!TZ).AASATCL09BD:`5Z]$"!Q@:,>.5#?K)H9CQ,:-C#9X_]JX
M$0%G70<B89[P".`E@0\?"7H$V).#2)`V<:"Q(<ESHH>7]8*$V1,@08@(*RY<
MT',A0@(68>@\5G'@TK4W`?U)Z7`#2H`>/D+(GIU@P)@;'=Z(:/.FBT8V.Q?U
MH=,@#N_B*HCL&>!#RP03)NI<*:&FP!439B[X&!!&BH@&*->J^L7[`)$<`R+H
ML6$#@(435?P4*%!FOH4U`+1P/\!F&IL&;]SU1``AZ%&&#2",,`)[#%[A!X,7
M)#"$``?L@U-PBO3!1EPJ2!:`>@F.8$$!5EA1@`4`E"!?=258`<`)$?"@@!L-
MB`=*-FP0(P(;'80110@7`&"%!7Y8X0>1)YR@HO]\)?IQPHCZA3%'3C860@U.
MQ&B(QH`%/FG%"&JH844)%EA@(HDEEI@%"'J$$$`.'5"I#(;8D&<'&@[TL$(!
M(Y@87PE5-)GFF07(9T.9$_00Q@%MZ%AE)COJL(X$#1S!XPU1K-#BDO/Y4623
M\Q50`I^B>FH!%1$\(<$!6#SJ2S`<V:$"'&P$D8,75:"XY)E'&NG'KJ8"X*FG
M5EP@A@(QY=@/AFP<X0$;;4@0Q@!5C/!KD:$2F^:#-G0Z;)%^K!$""0V\`$=$
MKEZ2S&YQ_'/`#1\&:@6#)19:J!\*%CIJ"4J6::H?6N30@!TB)#*1&V[\A`84
M/5P@GP4'=EN=I_,IR.#_J-X.:V8!"3QQ0!PWV:@"I4<HP,(*)9:@(J`EV+`D
M>T-:,$(!+B])L7Q7]*#`/%"E:\DZ(`<5!!0A"%F&!<_]6J:8[AF9Y@ADJ)'%
MOT1:P84/!\#11B)0N3$:"3U,L,4(69B0Y!4`G`@""'Y,P)D>$U@`@A5DD%'J
ML$]R`<`*JKY0D(T-P'$$$0/X`<+16;0HIH)M7[""%A?$W:<-9?A*K'5JG,##
M&_B\X7,E;M"DSPT)@&$WY39`O>`$6OC0PP!1B)$""U.\IL4598#0HK]DV@"%
M&SY+P9$4-WA1AQKU45Z&Z@7H$8$7`;`P1`P,Q#!$%`.$8,*(5'Q+114F%*"&
M_QEA2.`UX&\0$0((]-EPQ0GT`6!&"#U,,7T++4"QAQ@)1&""%67X%HDFD*`5
M=(`?=-"!)PQBAP-@(`2XZ].OR-0V'P0@!0Z(`?YHH`0:M"`&,6!!`B90`/=\
MRE-<$(/?$G&`!@XA!!8`E'5,\*`%Z<&".-`@!VO`0Q<HH04X&,`*'"1`4?%I
M"P,(@@X(1HB2)6`$)4";H;H5@0'DL`5*R*(2&/!#%Z3`"WH0UK=,]*`('$`"
M;Y""`C%A!QV@I@TYZD``K*4&,I2A!"8@PPCTT`,<M(`!-&#`#D`HR!T8<@=*
M>,(`_O<M/P1J``<`'*5>L"HB),`],2Q!VDYD@@M8,?\'U"LD`US`02YND08N
M&(`9K#`!,JGA6R,:0QSN\0(VS$H!7N!"H5SFA^5I00R!=(`#$%D#)6@0A#NH
M'@YZ$#[V$`MI8C@`K#[W""S84@5S:$`'!J`B%YV@#EDH`P`2L`<L;I$!-:#!
M`X!@A*\8`0@TJ,$0+G`OC8T`DB([0DS>,(85V&`-)S!!%50DLPD,8`A*<`$#
M!%F#!V!```I``QH4(``CM*`&#'C"%!P&@K@U<@T!F.4;\,`&607`!%`$`!5F
M5@=R:I&+,X`H&@@0!`(H``.!W`$4N,D%,CAH!";H@0,64!`\%`P3^."'!PBW
M!@"^)WPC,.@6%:J$F!+@@#K_2!A:W$"'("R@!5H0H[:H$(`@V*A1;9`""ZIE
M-X&FCGTQNNA"JRH``DA`!W.`R-]$<(`%8$"A49@`&0`%2POT0`+YL,-C;D#"
M-52A`"BU@0\<@%$&M&`!05!J/SQ@D@,H8`8N<,`(350"/00@@P)0@1N8B`D-
ME0L-QIO`S`HE3BU$X0DU".T,%""%-\1A(C+8K#-0HH`+V&",93#!$-!P5$&L
MM@-1,($F)\">PP%`#P-P@`M\R``,*.``'*$''&10%L[*P&\=6``-8A""HYU`
M@'[P01#>X)$W2&``(^@H%?BU1Q[$8`<M$$`0W-('?'A`4I)Z2QLZ((#0!F`%
M>O#"_QZXR``"'%@WF=#0&Q3@@U&!H$P%(`,`(I`"A;H`"`20BJ2`YXYQ"&,!
M9K#6MT80@A:@P0Z$J``:$C"J]]3A0=:)``ODZ@(,I+@@YTM'-'ZA@F"TP8$!
M$!*1AF6%*D0`#7!000.D@(80].N9$:`L!CI`$SL8E1G:^(77#$R`#_H0E3%0
M@@`&]C=*:*A1%+G3`#8VHB&IX0(\""T#*-0HD13C'3+PVCSZ$(<7.(!]1XIA
M%<`P`!JD6`4Z@%8%]DRB$[#O>"#P08FWN%M&+?D;@DCS0V30@2$<SF9`CL`"
M/A*4XFK+#^Y9@0-0'"N%)*/%Z/B%#A;P@.I1KP8"D$*=J/^9"!$HUAX-"$(/
MOG>B)X$I!"D`X0,4H`(-)<(?"*-1$'QP`A,-B68A&,(,QH*/!J"!6EP8U<S@
M9X,>0$&+`NC`.IAMB#XTX`8ED/&P2!0"`<#!`WA(G\,&10:D1:$#`**O5)21
MKE]T@0`X;0$&,LMO1D"$#G$XP@'$(-A-/?;//&C!#H`P(\_U!Q')2)@=?L""
M7]E@2$6Z0!088`1H:S,`$^`"4!^4A>HD((<,V*UHTB&)/APA#.&S7)&HD``!
MK-D-1+C`H,Q=@A"$H0,P@4/0BH&(7WC`#40A@!3HT7'AP`$.%3C`$V(,@#*0
MX017L($9HD"]&1`@N':0!B*`)_;_`PQ!#VK0W9&>,P#<'J8!$E"!`WZ,QQ\K
M:00^@`+U4"P!?`@"0X[H@QV>4`?J?DL-)AB``'`2$31$H$F_,L$5U$"%$+!`
M`8WV-=D580T/G`$8>&B[(D2@Y0KD(`0MZU8!GH3=A-H8+1Y0[,L/H8)FF4P/
M5A#3\NV6@&1B@,YON$$$K#4?,EJ`Q+DU\AL:D"7AI]H#43!2/8^D!1X(8"):
MWJ:9B/4^,]E@`@G``X4A%OM6=L^0#`AV<,)W#%D%/'UP!KNQ*@20`&M@`=V2
M-M62`!FT6_X@*31A7L[0#G31`3G0`U5`!KW$'H$R63R$!@,C`6C0`W5',X>3
M.E7``X&$_P$2D`Z"UW$/V`<)(P4^\$H$5206H($*L!%L8%\X("P6>',K8S8N
M<D.P,P90\`0Y$`9$T`'%L!L'AA8*(0*2(GPO0#!P@!!2D(8J\`('$``E$$##
MHDDK@`.YI0`_L1',P`9HJ&4OT`%H@"DA0`4@H$N`4@9;D'K:M0,*(`$@)P4!
M<`7VH2*48U!]1P?+,`EY*`)'0`+;\X935`53T`)!$`UNH`($$`)6\#VPUD@D
M`@!U4`=K``9K<`54Z`"&(2N<@P\300>18!8=@0=QP1$-$`:R-7\CD`8!$`,N
MT'.\L88O@`]!T2X,]@1BX`5:4`5KL#QOF"*C,@`N@%%&8#Z50O\$*%,HF60!
M:A`"PS0#:/`'C#$):;1$;4@%XE0?@:(&*P`%0+"#.]('<#`'4:`'!0!.C520
M3%("4V,B6R`_VY$#!_`"SZ`#</`'@N<(4A$46A8';C`'*G`#(3`"Y?8M)>`#
M2N``[#A1"D`$*AD&,<`#`V`9%T`%6\`%95`=)'(%)Y<%(9!R@60$SB(X;K!G
M9.`B:C!0%J`'./`$+A`$RA8.WB8)^@`@86`&)](BH@*24>`"!M<%_?$+;&`$
M@364!NDI!"4W"V(B2&,FE8,J0Q`$<Z!&6B-\Y6('04`"+/`:K^,#WU.09>`X
M6A`!$:`%D*,9@E4W-D`&"2(J)$0Y7V+_=W@D5*5D!`>@$%I#!'#3-C=7!4<S
M``FU`&P`!TY9"7)1`4'@!9M$(O*!>0"&!G1P$M3P51NUB@9)).WC,FGC!V9C
M=V70`T20AC,A?'&`!GN`?/BQ-HFY4K!F`5<@8H8R'W@74*^H22H3:5F0.%<P
M`=<9`E.@4,HH`!+P`E(P%A(0!6N`FW5792!P`4.P<CRR@^[X!Q/9"$ZI9N4"
M!4VU22!P`C,3!32``8R2:3D2#`=@!#0P!`EP`48)>Y\B*@.%)J]4)-51!390
M!53@`^7C#\)W!`%P+6-9D*$R+]9Y`@EI)B:B(//F*=T"4!$0!8;T1S3`;0B'
MBUDG<'Y0'18P_P#X@P8<X0:82)&_(`$50`"O]RWQ06D.8&G0L@Z$T`=!,`/5
M,P25<0$GX!YV-)W8PG4=:@'R)0$2T%R-H``1$$53UJ'#`AV),YUHTD@J@Y``
M9`-4,`$1T`-[0$K)1`-&T`%S<!(8X6Q1,"K?`@#YD4P*X`%=@XF@^0L-0`"F
M&1\#1V/:900GL2-TP@8.Q$,MX`([D`)1`!OJ04(*8@%9("HT-)8%4`5/(`>-
M`@E95V5DVD@@]B5F@VN8-"+TX2+N,0':$0!#\`0QD$'HM``'D%6_I@,O$`0A
M("9$>@65-@/W$'C3!PG%,!$'D`(^A8(#-P%1@#\$T`7*8"5ET0%&H/]0<X5*
M#I`"8H`],%D')`*'!MDB`?!V7LH(KG<T4D>F#7(%*8.K*Q`!(0`8/?`Z`2`&
M]\-#<_4`^?8&;R$,BR$"+Q`&ZBIUM(@#26"'_0`</1H.;``%_')'1,J9@_8L
MX6`-A.`,*1$$`H`!YF1BV[6R4*HIUFJ050`"`S!2PG<`&S50>'0DC30F?M`9
M_>JO`Q``L<,#*8`#."!,P[1=J%0]I-0")"!@=;$;;3`,L?*(:3,H6DH#0'``
M:%&`);&G:%8/&!`!NK.F17("$E)D$*<AP64CSX`6-#$4!+``)SL#*:M0-1`#
MF2)UTSDF\`-)G@,)#2``8M`#?I$`6C`"[%K_)%E@4$<[2AWD0PDEN0ME;(2T
M4!H'4<&*!XG`#"'`)(."1"XPJ)-P#`K1!XSR`B2P`MUC)N]QF&%&2A86KR5!
M$4&@`'1K!!A@MYCJ`WP[-:+2N#R@1'*I7CO@`$?K`XGCJEK``L8&N894N5F$
M/RWP`#,`!!CP4`N`!AV`1ISE,WU``-AW(FER*BRP;F\P"6*H6JAQ!#DP1$7X
M'ETW9$JP`+3B?G\0#5D%(*O2`7.;`T/82+RT/&&F`$KZ"!+P60N%41$``!,@
MDE:@CACUC31``]>+`>VT``L043/5`0>0$`F##W:`!;W7N3E0!S&$M7K@`%:W
M-9(@$IQ#23F@!66R_W]%,@(K,*?=12F!&PDB8%3"X`S'T`#&IREC9`59`#$V
M,``,H`"@"0EI=%-VZP")N[A7,`()$&`:'%%7=4:SLEGT@!)G9V#]4&@5V6\L
M0`56`(E.,V)+R1N3T`P`@@93<#LW-V5F\DO40P(6IECXJV3]("E=H`-<Y@6X
MV4AQ\QX^,`0U0&;"%Q'T10!_6([?<@5<T`-`H%3.P(/:L,G>``S'<`?:P*,P
M%P`@4)2^DHHA,`-2@`<2,`E-YFY1ECI64&Y-4G_KU0($X!A3VW3[E@Y[2@`!
MP`7@$H<$9`,7,*=`L(3X^WD>H`!:@',#MP5>8`0'5@I!F3;_DR:UUW/`T/^Y
M&G)G6_8&;!`''0`%9"MO,W,T6KI=.S`#9'8)O%$7T!(44B``%$@SRY=]W-BS
M/#F*PD`)P;6J?'M/1+5&HQ"4\Y)WW.P#`K`.M.L+T=HL4O$&0<`"%S`"@<(O
M`S4SBZQ0+6#`+@PZ2O4/=D""R%=^^I(D^DF).UP-=H8'63=_3F)8"G`$""T*
M.A`%<V-N)3)B"T`/'@#.:D$:YOP$$$0FUH6O9&`&`Q`#-?#.CY?3DT`/$7'2
M8--4NX1K1-(R([!WZ.1W.G`,E=`',GT!8^HIGI8`-]W,30<%^<DV37*41-`H
M0UUV7OD?=$`$/7`":O`>\6$%I^S`43`#N34#01#_?6=W"?]1`1)P`SVP'I"U
M>*$",>D9!1@5`S.B0)PET&^`!M&<U@$7`C?0!E0-"B)`!&50!R`I*`"0`P9Q
MUX<PT0H@!F:@2^]3(I4#13XP9`LU9CO2#I<`!VA``F"T!6P#1?*!FI13`C$"
M0C1`5-_;V9C8(3Z`-$6D!RD0*T9UVIL@`A)`PVLL*&00`%$I$BG1;=:P(]!"
M!`$@I6NJ.$;"!4[M`-7#<UE##"(["&]1$$N$!5.K0-;0@$LH`#\2LRFB('8T
M'W]=+?7]7Y>E&W,">H_@CV\P`(HW+-UR`O+U!N$6T9KP"U&@-XW$!2M`!$?`
M5:'S`A40<O$0!$_@!=@)_S_E5R9HPS$Z;%F\90S-MEEGAVD;(140P1I1X`,3
M`*BF0EI)$D72Q3$L(*[LJ`)DC0EGP*4\D.':PB]04'T(,]*>`(1AL`9'_BT)
M$@`'H$_]4"$5``=!,`8-8S5<H'P*DBM`Q<3B^J((P^-X'7WST`ST0!!H,`9"
M1#=62J(64`<F\")E``:>M`/;E70SLGN7L!L=J06N2B(F?@-O<`35%PK/<`!>
M@*\"U%%3T+T((P$+L`=Z`@`BPB^2J+B/-0$2MEZCE&\&L34^LQC&<!6H6]Q1
MJL;'!;RXIB*A4D<VH!]#T`+#-&AFU0YN70ANQ`;O)E9'$A^%D@`D<`02\*R=
M@/\,)""0?XHO$S`%>"$&V?/`_C)E[_4E)1`A8@!(U;-;G=<,ND'A@Z"P':``
M-Y`"+TE/YI8Z3O(IZIXZ$Q`"`[`''13O"U!]RG+&E9`/;W``4+#13[)\O\(G
MJ=(!.*T6;;$8")9@+29LDA(1F_P'`QX1<M0]W](MN%D@5Y"8-V,D9M(G`#@%
M,5#!U2-@;A`7G(,'RQ)<R3`,;4``-_`$49``*R![M'K#)D(YKV0V96(%;6)%
MZE1,3Y!O#S$1`0TI<I$^7D`B:?U,*Q``)*``N5$6"9%EY](/(1B"FV4/<'`2
M=FT0ZU<!`O"Y8TD%LSI&90(?*Y``47"D"J6UW!8Z\U#_$5HF%1(0!&B`%V-0
M&1$@I0KZ(&.DX=;".EX0!3AP3C]D!*PIZ9Q@=B<]!!%@`;@MDIP4(:!!!#^@
M6$'1`.[P$)XL#%H!1W#`AK<K`&$`!7MAZ6-9OFDM-W!Z\"Z0LC.P`&!W!K\G
M*5)!J5U!`H_?/WI0;GU2(OXR<$9R-HD#`/_G)BF012:F<6CPG:GV[(O0>W&P
M`#RP`@'T7MA?!O6!:U1P`EJ0`+J:`S=P`RJY__P/"$1$`C=A)`Y1`0D1>B=7
M(%M6(!9^E9:65IF7E1,^4U`T#$I*-4`+'4$$:(("83-3`SX7)@``DS9^9656
M)XY4%B67%A8C(",C52L^`3@Q_RXU##LN+0(=;FX-;WU]?]W>W^#AXN#;?6PB
M02U19E56PGX%)05697ZU(%95>A<K$1$A``.&\+=BQ80)-M*D`3!,30$3)OQ8
M<+<)4R:*EDI,T!(B08\>`P*($9-H0`(?(59<T..'RAH0(`H4L&%#II\2)\B0
M*5/@YB4K):Z8T!-AP!0'-%PH9<"@A9$@;MJ(Z*-#Q[9Q6+.&DR%"AQLV'A:T
MV!,A4XE@5@!8*0#"D85=-6=FZKGIHLP"`.15FG?6`I>:$C-1NECBXL1AE2C1
MG&C#2C$`:QR#('-7)M!>)ZQ8.&'B"L.)O0K'&[;V0@@O1Q^$VA$CAI(93]G@
MP<-&!_\<-C+::-W-^UN?`P*4#.EAQL8(>;MP7@$V\:+SQ!/]I`4@],0(-3S]
MC'"\?4()2F5V`J!R926`G06`99;)LPKFL_#?RYM;IM9$RP6R4\E[+.W^"2'T
M$`4.#NS`@`M,,>64`E+`P4UO$$;H#54'8-!4%"%440!G)TA4A1\GN.<<17;)
M5%,9QHU@HCN=W0?`3&5,H(<R`X@!Q12R`&"#+O54-M==:HPXS%F63.#>"4%=
MH:1C:WTW@3(]!+#'$RV$TAIK-#R`@0('J."&!W@\*.&8N\G@@0A2&*$4(CX4
M``8^91BSW8@D:F;!/%8H>58\N<QS#!54#!5!`@-$D8(##-3_H"@T*7CA@QDO
M$9E=17=586D[,GU(AAK;$0.3#1-<,&BAARHU"E-*Q)`H$`(HT,$<;;31APQ4
MB4GFK>+TX8$'?4B@0`O3Q)!"%`EH488)2*XUS++166)?,9H!8.2,'84D!@M#
MQ-#"`]!$TYH#5]*@!`YB!.!H"%KH860O51QDTR4R\M-/"#YX%%(4+.#05)4(
M[@`N@DJT@$&K'9Q3%5B\WJ&KK;@VW`U5;6A#!P$SB`*-`\,ZNH(9WS&+&(CM
M[O-/`EZ$%``/*1#HC`NA).BRP*U:Z(!22SF`0PH\D!1`(@$$,,#//_<<A1@I
MI#P$@4Q)P[(23"&88`T!8[```1V\_V'U-B*(X$%57]KQ@@@.AYUK'RH08$0+
M";J6Z@XW%^UVRC@0B*AK+=3-M,L&-MW"##,,K`#5N+%AS@\"S-!M@JRUUH(S
MHYC:N`NMT:QJTJVY''#?K1)P@`YB=]XPK;I*0<`"&,P`+`.MJ6UW:Z>ZG*#C
M=;<`!`9&"#!U$!UTZ88.69?3QQDJ=(#&`D;PO7KJDT>S0]Y.*Z5M['P#843M
M"Z"!>Y=OQ,JPY]SS)@,;Y^#1A@=N!*&``*6;[DSDD$//=_2TVZZ`]4%TJ0,;
M;^R*AQUX9"U"&X+[`]:R5A54$$`!"UB``*8W/0Q@8'8.="#U%J"`^1$@"/63
M`!R\\@8SB?]O5U+97O=&.`[0[>I,6GN#"@[0@0ZHHH(4M"`&9UB_`TC!2_[K
M71^RMK4NG#!K9KI*-\[4!JYD[TR[4F$#Z"`!*1S@B5*00A-58+6(M:%_0.3*
MKJJRC6OHP`,.(J$8LR(#6K'!BSN,51EW>,(?9BU6/V2CF4[HAG+LJHQ:NZ,,
MK/*@/M31`T;<(N^XTKLR&M*0/`1D&P%)*P\`<(=3<>2N1#C&2EKRDIC,I"8W
MR<E.>O*3H`RE*$=)RE*:\I2H1*4(7J!"J\"!BE*P`_F^X@'<E+$!*M"5'<9G
M!["PH0TOB)4.<"G$;DBEEFZ0@`P:(,O_V:$!;(!#&^+0!VJV00+_^'/DUX)Y
M&PDT``Z[_.7WM"8'.U2`F6^``S9N*,L*L'*/7P'?-KP"3'3J`(ZSTH$4SN@!
M'.Y2!M]P9!Q4((<V0--K;/":"*XF@Z_=:AN./$+^W$`'*<CA?GETPPWAP,P7
M-.`(#9!`+W=)!R])P&IPD(`'OF&UVC1@F.![@T3!N4MI[K("$A`!3N\I2QV`
M]`AVZ)($#B""VH#EG&TX@JSB\+\W5(`.S\QE`SS0`&C"80YO>`%(H\D&":A`
M!78HZ1NP(0(Z1%.F=FCI-\S9@`,<004@K:H*)2!2.VPPC&3RP!&T"D!9+@`&
M1W!G5:7BANP!M0%%[8`"L/D"K:K@I`VX_R%BOW$;$>R5HW'`7P.J&2OP+38.
M?'#".5GYAK1Z+:X58(,1.+"[5>+A"$ETJCNEV08I"(`)$JA`!8X`OFS`]9EQ
MM5H#@-FE6F8/JLY\P9EL]88&=&`#"S#H`9IKAVLTX`5PH*H=P$:F/KR!A6B0
M`D@?H($#=-6%$C"H=-'0@9!20`CM;>L!"/"".2CV!U;YAD>;>$%OXA(.!UCL
M;0X@A`/8@0\P>($*G$L`8+)!"N:KGQU0\`45Z."<*F`#!DM+T?D&(;=&6,(;
M'GS!TE9`"G0X`'OAD#TV7!"HP)0`U>:@6SHH=L%G"&@#?L"$!<#6#51K+@#G
M:\-<WDH$#<B``?^6G($#/*`)/R``$I:,@"*\0`$;6+(!@%"$)GR``QAP0I8Y
MT`$*&*`)!G""%/0K`0P@8,D<\#$'F*!E4W#@`P@`0@8VT``!O-D`2R#`$9R@
M91@T@,(J:(,=I+"`/R-@`14H0J'?L-H&!($#5"Y"`V#`@3\_H`(+P+0!'MWF
M/R]!`&^`@98SP-UN-/<'2!!`$3@@:B<<X`>J7C(*?M!J"8G`"$)@0A(VH($'
M//D'%-"`$Y*```A4@`E"H``*$-`$#"#A"WQ0``*^D(<D+$`(W<Z#$!X0J\+"
M`0YH3D(&-,"!(T!`"$Y@``<T0``^?"$#4C9`'):,`SY`(`]!@,`&AOW_A1]0
MF*-6R\`7DH`##<#@VQQ0`@4@H(`B.)L)&N!#$LY\``1$6PEO;L,2-)`!/K![
M`1I`0`HR``$.2.`+2-@!IAU4CG02H-A.^`(3E,"$+P3!WLL>.09R.4]*BD,$
M><`SK05.W@H8@-V=_H("#.#R!M2[`QD0P@_B\.:J;J`)CY4"U0\@ZJ$+00$?
MY8,0V@`!)E2U`T+X\!<Z0(<IL^$+"\B&`V&-@+Y_@`!)^`+"[6#Q47.@"!0F
M@!0:4`0T6+P"$(!ZLQ>P9)!.O`%-:/(1!/``("A]W@9001.:@``..$&E2E3!
MQ#0`!"?0^PB>)P"MJWH`%!"@JK5Y`^=Z(X(-_WQA`\#G``J>?(`E`Y\)".@`
MU=T9!!@0(.L':``"F'`$"639FT<8.PR6$&LZP/>C*!`"'`1^SI<K?NX-F'(7
M"DZ'-SP`!4#X`@)@D'0%4)@.4WT!!G#`!`ZTG,+G5`$9L``6UP$08`#'QP$$
M,&H=(`$LUP5-@`(X9009X'E+$'P;0`<9D`=(T`04UT2.-5^LYP1-4`%VX'D*
MP`%(X$T=X`0^EDX>H`T0X@%H(`1+@`(PH`$80'P6YP22I@%L``/1Q@=G]G/8
MEH(<`!92$&PHX'L8,%Q[=4YGE@$3AUL0\`4P0(0&\%WWI@!3U@;-E@%9EP%%
M\`%D:``?@`(4EE!TT/\&,``!:CAJ"@`!"(`"3A!W20`!+2@$&8`"2Z8"2U8!
M;\!R'K`!T99U&_`#:%9R$(`$<:!SPZ8!"Y`!"'``=$`'<!`$(]@$!^`!&/`!
M"O``W#9M&F`$3J"`=,`K$-('<+!ND4<!$B``2R`!EP8!!S@#<:``3&"+32``
M%:``:/8`,$`!7Y5D&A!Y3L!1$G`-SV0$'DB'D$:''LAZ;:`""%!L&<`$;4!Y
MMH@$0?`#UYAR@`8$"$!%<!`'E'>,30`$[O>,>7`$JS4'4M!L!_@`;P!\'O4`
M'-``VF:+"'!["_",'"``+T!LD;<!$I!L/R!6!W!J1;`$J45YWYB#D?<`<4#W
M`8&F5T87#B*05A+P`FS@41'#3"D5*T7E2XTE3<X52VR0#5*@:()36FGU/5C`
M!D?P2CKP6+@$`3"P6W:082>66D.%7&V@47"`75)06AW0!A45,3KP`DT$4H)8
M1[R54H&5:.?4!W=P3DQ$6R\0?2]P3EG5B6TU!WC07+CT41[U`GLFE@"D`HV5
M6]FSC,V%32+@!BI`6[VTD:DD`VD%!TY@!`860*F$*WWP`P=`<X4Y1K(15CG9
M7%6QF+<B.-M`F)+9/>=@!YJI7!OD!I<Y)N;@.Y^)F8(#1UZR0Z,I(700FGR9
8FA$B*X(#!W*`E^#CFJO8!V;5FF,2"``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
